50% OFF
MarketBeat All Access
Get 30 days free. Save 50% your first year.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
S&P 500   3,655.04
DOW   29,260.81
QQQ   274.37
This Device Makes Creating Voice Memos Easy
Goldman Sachs Alum Sounds Alarm on "Next US Crisis" (Ad)
Three Consumer Stocks That Could Outperform In Q4 
Will Synthetic Biology Firm Amyris Post Net Income In 2024?
Goldman Sachs Alum Sounds Alarm on "Next US Crisis" (Ad)
Comcast is an Asset Bonanza Priced Cheap
US stocks slip deeper into a slump as recession fears grow
Goldman Sachs Alum Sounds Alarm on "Next US Crisis" (Ad)
British pound plunges to new low as tax cuts spark concern
Lights out, ovens off: Europe preps for winter energy crisis
S&P 500   3,655.04
DOW   29,260.81
QQQ   274.37
This Device Makes Creating Voice Memos Easy
Goldman Sachs Alum Sounds Alarm on "Next US Crisis" (Ad)
Three Consumer Stocks That Could Outperform In Q4 
Will Synthetic Biology Firm Amyris Post Net Income In 2024?
Goldman Sachs Alum Sounds Alarm on "Next US Crisis" (Ad)
Comcast is an Asset Bonanza Priced Cheap
US stocks slip deeper into a slump as recession fears grow
Goldman Sachs Alum Sounds Alarm on "Next US Crisis" (Ad)
British pound plunges to new low as tax cuts spark concern
Lights out, ovens off: Europe preps for winter energy crisis
S&P 500   3,655.04
DOW   29,260.81
QQQ   274.37
This Device Makes Creating Voice Memos Easy
Goldman Sachs Alum Sounds Alarm on "Next US Crisis" (Ad)
Three Consumer Stocks That Could Outperform In Q4 
Will Synthetic Biology Firm Amyris Post Net Income In 2024?
Goldman Sachs Alum Sounds Alarm on "Next US Crisis" (Ad)
Comcast is an Asset Bonanza Priced Cheap
US stocks slip deeper into a slump as recession fears grow
Goldman Sachs Alum Sounds Alarm on "Next US Crisis" (Ad)
British pound plunges to new low as tax cuts spark concern
Lights out, ovens off: Europe preps for winter energy crisis
S&P 500   3,655.04
DOW   29,260.81
QQQ   274.37
This Device Makes Creating Voice Memos Easy
Goldman Sachs Alum Sounds Alarm on "Next US Crisis" (Ad)
Three Consumer Stocks That Could Outperform In Q4 
Will Synthetic Biology Firm Amyris Post Net Income In 2024?
Goldman Sachs Alum Sounds Alarm on "Next US Crisis" (Ad)
Comcast is an Asset Bonanza Priced Cheap
US stocks slip deeper into a slump as recession fears grow
Goldman Sachs Alum Sounds Alarm on "Next US Crisis" (Ad)
British pound plunges to new low as tax cuts spark concern
Lights out, ovens off: Europe preps for winter energy crisis
NASDAQ:IVA

Inventiva - IVA Stock Forecast, Price & News

$3.81
-0.11 (-2.81%)
(As of 09/26/2022 12:00 AM ET)
Add
Compare
Today's Range
$3.75
$4.00
50-Day Range
$3.81
$5.42
52-Week Range
$3.75
$15.78
Volume
977 shs
Average Volume
14,206 shs
Market Capitalization
$155.73 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$36.00

Inventiva MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
844.9% Upside
$36.00 Price Target
Short Interest
Bearish
0.38% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.32mentions of Inventiva in the last 14 days
Based on 9 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($1.76) to ($1.99) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.90 out of 5 stars

Medical Sector

725th out of 1,069 stocks

Pharmaceutical Preparations Industry

332nd out of 533 stocks

IVA stock logo

About Inventiva (NASDAQ:IVA) Stock

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases. Its lead product candidate is Lanifibranor, which has completed Phase IIb clinical trial to treat NASH. The company also develops Odiparcil, which has completed Phase IIa clinical trial for the treatment of MPS VI subtype disease. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company has strategic collaboration with AbbVie for the treatment of autoimmune diseases; and Boehringer Ingelheim International GmbH for developing new treatments for idiopathic pulmonary fibrosis. Inventiva S.A. was founded in 2011 and is based in Daix, France.

Receive IVA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Inventiva and its competitors with MarketBeat's FREE daily newsletter.

IVA Stock News Headlines

The Safest Option in Trades!
If you’re new to trading, then you’ve probably heard the wrong thing about options—that they’re risky, unpredictable, or difficult. And it couldn’t be more wrong! With the Hughes Optioneering Strategy, you’ll soon learn that the safest option for new accounts is options themselves! pixel
The Safest Option in Trades!
If you’re new to trading, then you’ve probably heard the wrong thing about options—that they’re risky, unpredictable, or difficult. And it couldn’t be more wrong! With the Hughes Optioneering Strategy, you’ll soon learn that the safest option for new accounts is options themselves! pixel
Inventiva (IVA) Set to Announce Earnings on Wednesday
Inventiva joins the Euronext Tech Leaders segment
See More Headlines
Receive IVA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Inventiva and its competitors with MarketBeat's FREE daily newsletter.

IVA Company Calendar

Today
9/27/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:IVA
Fax
N/A
Employees
101
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$36.00
High Stock Price Forecast
$36.00
Low Stock Price Forecast
$36.00
Forecasted Upside/Downside
+844.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$4.96 million
Book Value
$2.58 per share

Miscellaneous

Free Float
27,794,000
Market Cap
$155.73 million
Optionable
Not Optionable
Beta
0.91

Key Executives

  • Mr. Frederic Cren (Age 56)
    Co-Founder, CEO & Chairman
    Comp: $526.06k
  • Dr. Pierre Broqua Ph.D. (Age 60)
    Co-Founder, Chief Scientific Officer, Deputy CEO & Director
    Comp: $358.32k
  • Mr. Jean Volatier (Age 58)
    Chief Financial Officer
  • Mr. Eric Duranson L.L.M. (Age 48)
    Gen. Counsel
  • Ms. Nathalie Harroy (Age 55)
    Head of HR
  • Dr. Irena Konstantinova
    Head of Biology & Pharmacology
  • Dr. Michael Cooreman (Age 64)
    Chief Medical Officer
  • Mr. Jean-Paul Dutertre M.D.
    Head of Pharmacovigilance













IVA Stock - Frequently Asked Questions

Should I buy or sell Inventiva stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Inventiva in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" IVA shares.
View IVA analyst ratings
or view top-rated stocks.

What is Inventiva's stock price forecast for 2022?

1 analysts have issued 1-year target prices for Inventiva's shares. Their IVA share price forecasts range from $36.00 to $36.00. On average, they predict the company's stock price to reach $36.00 in the next twelve months. This suggests a possible upside of 844.9% from the stock's current price.
View analysts price targets for IVA
or view top-rated stocks among Wall Street analysts.

How have IVA shares performed in 2022?

Inventiva's stock was trading at $13.66 on January 1st, 2022. Since then, IVA shares have decreased by 72.1% and is now trading at $3.81.
View the best growth stocks for 2022 here
.

When did Inventiva IPO?

(IVA) raised $103 million in an initial public offering on Friday, July 10th 2020. The company issued 7,500,000 shares at $13.68 per share. Jefferies, Stifel and Guggenheim Securities acted as the underwriters for the IPO and H.C. Wainwright, Roth Capital Partners and KBC Securities were co-managers.

What is Inventiva's stock symbol?

Inventiva trades on the NASDAQ under the ticker symbol "IVA."

Who are Inventiva's major shareholders?

Inventiva's stock is owned by a variety of institutional and retail investors. Top institutional investors include Yiheng Capital Management L.P. (6.46%) and Commodore Capital LP (0.43%).

How do I buy shares of Inventiva?

Shares of IVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Inventiva's stock price today?

One share of IVA stock can currently be purchased for approximately $3.81.

How much money does Inventiva make?

Inventiva (NASDAQ:IVA) has a market capitalization of $155.73 million and generates $4.96 million in revenue each year.

How many employees does Inventiva have?

The company employs 101 workers across the globe.

How can I contact Inventiva?

Inventiva's mailing address is 50 RUE DE DIJON, DAIX I0, 21121. The official website for the company is www.inventivapharma.com. The company can be reached via phone at 33-3-80-44-75-00 or via email at finance@inventivapharma.com.

This page (NASDAQ:IVA) was last updated on 9/27/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.